Paper Details

  1. Home
  2. Paper Details

Vibegron, a Novel Potent and Selective &#946;<sub>3</sub>-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study.

Author: GotohMomokazu, KuroseTakafumi, NagaiShinji, TakedaMasayuki, YoshidaMasaki

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Vibegron demonstrated efficacy and safety in treating overactive bladder (OAB) in Japanese patients, with improvements in symptoms and quality of life.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Vibegron is a novel, potent, and selective β OBJECTIVE: To evaluate the efficacy and safety of vibegron versus placebo in Japanese OAB patients. DESIGN, SETTING, AND PARTICIPANTS: Patients with OAB entered a 2-wk placebo run-in phase. Once eligibility (≥8 micturition/d and either ≥1 ur...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.eururo.2017.12.022

データ提供：米国国立医学図書館（NLM）

Vibegron: A Promising New Treatment for Overactive Bladder

Overactive bladder (OAB) is a common and often debilitating condition, affecting millions worldwide. This research investigates the efficacy and safety of vibegron, a novel and selective β3-adrenoreceptor agonist, for treating OAB. The study, conducted in a randomized, double-blind, placebo-controlled trial, found that vibegron significantly improved OAB symptoms, including frequency of urination, urgency episodes, and incontinence. This research provides evidence for the potential of vibegron as a safe and effective treatment option for OAB.

What does this research tell us?

This research provides compelling evidence for the efficacy of vibegron in treating OAB. The study showed significant improvements in OAB symptoms, suggesting that vibegron is a promising new treatment option for individuals seeking relief from this condition.

Looking at the bigger picture: what does this mean for your health?

If you are struggling with OAB, it is essential to consult with a healthcare professional. They can evaluate your individual symptoms and recommend appropriate treatment options, including medications like vibegron. It is crucial to discuss your concerns with your doctor and explore all available options to find the most effective treatment plan for you.

Dr. Camel's Conclusion

This research, like a camel finding a refreshing oasis in the desert, offers a promising new treatment for OAB. The study provides evidence for the efficacy and safety of vibegron, offering hope for individuals seeking relief from this common and often debilitating condition.

Date :
  1. Date Completed 2019-02-14
  2. Date Revised 2019-02-15
Further Info :

Pubmed ID

29366513

DOI: Digital Object Identifier

10.1016/j.eururo.2017.12.022

Related Literature

Article Analysis
・Effects of vibegron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.